Thus, combining PD-1 blockade with STINGVAX increased the anti-tumor efficacy in many tumor models that did not respond to anti-PD-1 alone, which supports the rationale for clinical evaluation of STINGVAX in combination with anti-PD-1, particularly in settings where patients failed to respond to ICB monotherapy [135]. This evidence concerns the gene PDCD1 and neoplasm.